FDA — authorised 3 July 2013
- Application: NDA204242
- Marketing authorisation holder: EDENBRIDGE PHARMS
- Local brand name: ZUBSOLV
- Indication: TABLET — SUBLINGUAL
- Status: approved
🇺🇸 Higher bioavailability BNX sublingual tablets in United States
FDA authorised Higher bioavailability BNX sublingual tablets on 3 July 2013
Marketing authorisation
Higher bioavailability BNX sublingual tablets in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Higher bioavailability BNX sublingual tablets approved in United States?
Yes. FDA authorised it on 3 July 2013.
Who is the marketing authorisation holder for Higher bioavailability BNX sublingual tablets in United States?
EDENBRIDGE PHARMS holds the US marketing authorisation.